Background: Accurate staging is crucial for the proper management of patients with
nonsmall cell lung cancer, especially for choosing the best treatment strategy. Different …

PET/CT with the tracer 2-[18 F] fluoro-2-deoxy-D-glucose ([18 F] FDG) has improved
diagnostic imaging in cancer and is routinely used for diagnosing, staging and treatment …

This review summarizes the current literature and tries to define the status of nuclear
medicine in the clinical workup of lung cancer patients. Nuclear medicine procedures and …

This communication presents an update on the current role of positron emission tomography-
computed tomography (PET-CT) in the various clinical decision-making steps in lung …

An estimated 180,000 new cases of lung cancer will be diagnosed in the United States this
year, and lung cancer accounts for approximately 25% of all cancer deaths. The overall 5 …

Exact staging of locoregional lymph node (LN) disease in non-small cell lung cancer
(NSCLC) is of considerable clinical interest. Computed tomography (CT) is not very accurate …

The availability of clinical positron emission tomography (PET) is increasing rapidly in the
developed world (1). This article reviews the role of PET scanning in lung cancer …

Lung cancer is the leading cause of cancer mortality in the United States, with more than
170,000 individuals diagnosed each year and more than 140,000 succumbing to the …

Combined fluorodeoxyglucose-positron emission tomography (PET)/computed tomography
(CT) imaging has the potential to become the new standard imaging modality for the staging …

Non–small cell lung cancer (NSCLC) accounts for approximately 80% of bronchogenic
malignancies. The choice of therapy options, including surgery, radiation therapy, and …